William Styer to Susannah Styer

Styer's Regiment is on marching orders, but he believes he will either stay behind or will have his resignation approved, as he received a Certificate of Disability.Styer, Susannah1860s (1860-1869)Fort Pickering (Tenn.)600ppiCivil War Home FrontDC045This Civil War Home Front collection was funded by LSTA

Letters from W. J. Kerr and Henry D. Styer

Letters concerning requisitions for arms and ordnance stores needed at Utah Agricultural College

Letters from Henry D. Styer and William Kerr

Letters concerning an application to the chief of ordnance of the U.S. Army

Comparison of circulating levels of FGF19 and FGF21 between diabetic (T2D) and non-diabetic (No-T2D) patients.

<p>Comparison of circulating levels of FGF19 and FGF21 between diabetic (T2D) and non-diabetic (No-T2D) patients.</p

Comparison of hepatic gene expression between non-diabetic (No-T2D) and diabetic patients experiencing diabetes remission (T2D-R) or not experiencing diabetes remission (T2D-NoR) after RYGB surgery.

<p>Gene expression levels (mRNA determined by real time qPCR) for genes modulating the bile acids-FGF19-FGF21 pathway in the liver were compared between the three aforementioned groups. In the cases of <i>FGF21</i> (<b>A</b>), <i>HNF4α</i> (<b>B</b>), <i>CYP7A1</i> (<b>C</b>), <i>β-Klotho</i> (<b>E</b>), <i>GS</i> (<b>F</b>), and <i>FGFR4</i> (<b>G</b>), the T2D-NoR group of patients displayed signifciantly higher expression levels compared to control (i.e., No-T2D) and/or the T2D-R groups. There were no significant differences between the three groups for <i>SHP</i> (<b>D</b>), while, the T2D-R group had signifciantly lower expression levels for <i>HNF4α</i> (<b>B</b>), <i>GS</i> (<b>F</b>), and <i>FXR</i> (<b>H</b>), compared to No-T2D and T2D-NoR. Statistical analysis was performed by using ANOVA followed by Tukey’s test. The different letters (a, b, c) above the bars indicate statistically different groups (significance level at P-value < 0.05). Share of the same letter between groups (bars) indicates lack of statistical significance. NS: not statistically significant.</p

Quantitating SARS-CoV-2 neutralizing antibodies from human dried blood spots

ABSTRACT In the earliest days of the COVID-19 pandemic, the collection of dried blood spots (DBS) enabled public health laboratories to undertake population-scale seroprevalence studies used to estimate rates of SARS-CoV-2 exposure. With SARS-CoV-2 seropositivity levels now estimated to exceed 94% in the United States, attention has turned to using DBS to assess neutralizing antibodies within cohorts of interest. With this goal in mind, we generated contrived DBS (cDBS) and whole blood-derived DBS from convalescent and vaccinated individuals and subjected DBS eluates to a battery of assays, including a SARS-CoV-2 multiplexed microsphere immunoassay (MIA), a receptor binding domain (RBD)-human ACE2 inhibition assay (iACE2), a cell-based pseudovirus neutralization assay, and real-time PCR-based surrogate neutralization assay (NAB-Sure). The DBS results were benchmarked against paired serum samples tested in a clinically validated SARS-CoV-2 plaque reduction neutralization titer (PRNT) assay. The results of an 8-plex MIA and NAB-Sure assays demonstrated highly significant correlations with PRNT values when evaluated with a panel of 86 paired serum–DBS samples. Both the MIA and NAB-Sure are adaptable to automated liquid handlers for high-throughput capacity. While neutralizing assays were limited to the ancestral SARS-CoV-2 WA1, this study nonetheless represents an important proof of concept demonstrating the potential utility of DBS as a biospecimen type for use in assessing immunity to SARS-CoV-2 at the community and population levels.IMPORTANCESARS-CoV-2 variants of concern continue to circulate globally and remain a serious health threat to large segments of the population. From a public health standpoint, identifying vulnerable communities based on immune status is critical in terms of vaccine booster recommendations. In this report, we investigated the utility of dried blood spots (DBS) as a biospecimen type from which to estimate SARS-CoV-2 neutralizing antibody titers. Using contrived and whole blood-derived DBS, we demonstrate that SARS-CoV-2 neutralizing antibodies are readily measurable in DBS eluates and correlate with plaque reduction neutralization titer (PRNT) values from paired serum samples. Moreover, several of the methods used to estimate SARS-CoV-2 neutralizing antibodies in DBS eluates are adaptable to high-throughput platforms